

Edgar Filing: BIOMET INC - Form 10-Q

BIOMET INC
Form 10-Q
January 09, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended November 30, 2005.

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____.

Commission file Number 0-12515.

BIOMET, INC.
(Exact name of registrant as specified in its charter)

Indiana
(State or other jurisdiction of
incorporation or organization)

35-1418342
(I.R.S. Employer
Identification No.)

56 East Bell Drive, Warsaw, Indiana 46582
(Address of principal executive offices)

(574) 267-6639
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is an accelerated filer (as
described in Rule 12b-2 of the Exchange Act). Yes No

Indicate by check mark whether the registrant is a shell company (as described
in Rule 12b-2 of the Exchange Act). Yes No

As of November 30, 2005, the registrant had 247,525,550 common shares
outstanding.

BIOMET, INC.

CONTENTS

Pages

Part I. Financial Information

Edgar Filing: BIOMET INC - Form 10-Q

Item 1.	Financial Statements:	
	Consolidated Balance Sheets	1-2
	Consolidated Statements of Income	3
	Consolidated Statements of Cash Flows	4
	Notes to Consolidated Financial Statements	5-7
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	8-10
Item 3.	Quantitative and Qualitative Disclosure about Market Risks	11
Item 4.	Controls and Procedures	11
Part II.	Other Information	
	Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	12
	Item 6. Exhibits	12
	Signatures	13
	Index to Exhibits	14

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

BIOMET, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
at November 30, 2005 and May 31, 2005
(in thousands)

ASSETS

	November 30, 2005	May 31, 2005
	-----	-----
	(Unaudited)	
Current assets:		
Cash and cash equivalents	\$ 98,382	\$ 104,706
Investments	8,075	10,962
Accounts and notes receivable, net	479,902	479,745
Inventories	495,624	469,791
Deferred income taxes	74,332	72,732
Prepaid expenses and other	42,496	35,980
	-----	-----
Total current assets	1,198,811	1,173,916
	-----	-----
Property, plant and equipment, at cost	595,981	574,398
Less, Accumulated depreciation	263,683	251,511
	-----	-----
Property, plant and equipment, net	332,298	322,887
	-----	-----
Investments	61,070	61,406
Goodwill, net	431,473	435,621

Edgar Filing: BIOMET INC - Form 10-Q

Intangible assets, net	83,511	87,835
Other assets	14,777	14,912
	-----	-----
Total assets	\$2,121,940	\$2,096,577
	=====	=====

The accompanying notes are a part of the consolidated financial statements.

BIOMET, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
at November 30, 2005 and May 31, 2005
(in thousands)

LIABILITIES AND SHAREHOLDERS' EQUITY

	November 30, 2005	May 31, 2005
	-----	-----
	(Unaudited)	
Current liabilities:		
Short-term borrowings	\$ 289,768	\$ 282,193
Accounts payable	58,127	57,021
Accrued income taxes	5,309	9,725
Accrued wages and commissions	60,226	62,171
Other accrued expenses	94,469	90,281
	-----	-----
Total current liabilities	507,899	501,391
Long-term liabilities:		
Deferred income taxes	29,329	31,255
	-----	-----
Total liabilities	537,228	532,646
	-----	-----
Contingencies		
Shareholders' equity:		
Common shares	193,780	188,162
Additional paid-in capital	67,673	67,613
Retained earnings	1,328,932	1,284,905
Accumulated other comprehensive income (loss)	(5,673)	23,251
	-----	-----
Total shareholders' equity	1,584,712	1,563,931
	-----	-----
Total liabilities and shareholders' equity	\$2,121,940	\$2,096,577
	=====	=====

The accompanying notes are a part of the consolidated financial statements.

BIOMET, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME
for the six and three month periods ended November 30, 2005 and 2004
(Unaudited, in thousands, except per share data)

	Six Months Ended		Three Months Ended	
	2005	2004	2005	2004
	----	----	----	----
Net sales	\$ 979,593	\$ 894,834	\$ 494,690	\$ 456,674

Edgar Filing: BIOMET INC - Form 10-Q

Cost of sales	274,106	257,087	139,611	131,115
	-----	-----	-----	-----
Gross profit	705,487	637,747	355,079	325,559
Selling, general and administrative expenses	359,635	326,765	181,453	166,305
Research and development expense	42,119	38,082	21,303	19,606
In-process research and development	--	26,020	--	--
	-----	-----	-----	-----
Operating income	303,733	246,880	152,323	139,648
Other income, net	313	(484)	(245)	244
	-----	-----	-----	-----
Income before income taxes	304,046	246,396	152,078	139,892
Provision for income taxes	102,469	94,764	50,800	48,693
	-----	-----	-----	-----
Net income	\$ 201,577	\$ 151,632	\$ 101,278	\$ 91,199
	=====	=====	=====	=====
Earnings per share:				
Basic	\$.81	\$.60	\$.41	\$.36
	=====	=====	=====	=====
Diluted	\$.81	\$.59	\$.41	\$.36
	=====	=====	=====	=====
Shares used in the computation of earnings per share:				
Basic	248,963	253,403	248,337	252,944
	=====	=====	=====	=====
Diluted	249,952	255,586	249,276	255,255
	=====	=====	=====	=====
Cash dividends per common share	\$.25	\$.20	\$ --	\$ --
	=====	=====	=====	=====

The accompanying notes are a part of the consolidated financial statements.

BIOMET, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
for the six months ended November 30, 2005 and 2004
(Unaudited, in thousands)

	2005	2004
	----	----
Cash flows from (used in) operating activities:		
Net income	\$201,577	\$151,632
Adjustments to reconcile net income to net cash from operating activities:		
Depreciation	33,599	28,969
Amortization	4,433	3,290
Write off of in-process research and development	--	26,020
(Loss) Gain on sale of investments, net	(132)	223
Deferred income taxes	(3,060)	(6,684)
Changes in current assets and liabilities:		
Accounts and notes receivable, net	(13,830)	7,724
Inventories	(41,638)	(19,005)
Accounts payable	4,301	(3,868)
Accrued income taxes	(5,555)	(7,985)
Other	(793)	(1,133)
	-----	-----
Net cash from operating activities	178,902	179,183
	-----	-----

Edgar Filing: BIOMET INC - Form 10-Q

Cash flows from (used in) investing activities:		
Proceeds from sales and maturities of investments	28,527	24,692
Purchases of investments	(25,185)	(22,284)
Capital expenditures	(50,653)	(43,511)
Acquisitions, net of cash acquired	--	(266,229)
Other	556	(3,131)
	-----	-----
Net cash used in investing activities	(46,755)	(310,463)
	-----	-----
Cash flows from (used in) financing activities:		
Increase in short-term borrowings, net	11,118	209,385
Issuance of common shares	7,718	12,766
Cash dividends	(62,473)	(50,872)
Purchase of common shares	(97,929)	(103,990)
	-----	-----
Net cash from (used in) financing activities	(141,566)	67,289
	-----	-----
Effect of exchange rate changes on cash	3,095	4,266
	-----	-----
Decrease in cash and cash equivalents	(6,324)	(59,725)
Cash and cash equivalents, beginning of year	104,706	159,243
	-----	-----
Cash and cash equivalents, end of period	\$ 98,382	\$ 99,518
	=====	=====

The accompanying notes are a part of the consolidated financial statements.

BIOMET, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1: BASIS OF PRESENTATION.

The accompanying consolidated financial statements include the accounts of Biomet, Inc. and its subsidiaries (individually and collectively referred to as the "Company"). The unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and notes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six-month period ended November 30, 2005 are not necessarily indicative of the results that may be expected for the fiscal year ending May 31, 2006. For further information, refer to the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended May 31, 2005.

The accompanying consolidated balance sheet at May 31, 2005, has been derived from the audited Consolidated Financial Statements at that date, but does not include all disclosures required by accounting principles generally accepted in the United States.

The Company operates in one business segment, musculoskeletal products, which includes the designing, manufacturing and marketing of reconstructive products, fixation devices, spinal products and other products. Other products consist primarily of EBI's softgoods and bracing products, Arthrotek's arthroscopy products, general instruments and operating room supplies. The Company manages its business segment primarily on a geographic basis. These geographic markets are comprised of the United States, Europe and the Rest of World. Major markets included in the Rest of World geographic market are Canada, South America,

Edgar Filing: BIOMET INC - Form 10-Q

Mexico, Japan and the Pacific Rim.

Net sales of musculoskeletal products by product category are as follows for the six and three month periods ended November 30, 2005 and 2004:

	Six Months Ended		Three Months Ended	
	2005	2004	2005	2004
	(in thousands)			
Reconstructive Products	\$660,154	\$583,867	\$336,339	\$301,385
Fixation Devices	124,854	123,041	60,675	60,328
Spinal Products	110,353	106,141	55,027	53,232
Other Products	84,232	81,785	42,649	41,729
	-----	-----	-----	-----
Total	\$979,593	\$894,834	\$494,690	\$456,674
	=====	=====	=====	=====

As permitted by SFAS No. 123, the Company accounts for its employee stock options using the intrinsic value method. Accordingly, no compensation expense is recognized for the employee stock-based compensation plans. If compensation expense for the Company's employee stock options had been determined based on the fair value method of accounting, pro forma net income and diluted earnings per share for the six and three month periods ended November 30, 2005 and 2004 would have been as follows:

	Six Months Ended		Three Months Ended	
	2005	2004	2005	2004
Net income as reported (in thousands)	\$201,577	\$151,632	\$101,278	\$ 91,199
Deduct: Total stock-based employee compensation expense determined under the fair value method for all awards net of related tax effects (in thousands)	4,450	3,034	2,301	1,501
	-----	-----	-----	-----
Pro forma net income (in thousands)	\$197,127	\$148,598	\$ 98,977	\$ 89,698
	=====	=====	=====	=====
Earning per share:				
Basic, as reported	\$0.81	\$0.60	\$0.41	\$0.36
	=====	=====	=====	=====
Basic, pro forma	\$0.79	\$0.59	\$0.40	\$0.35
	=====	=====	=====	=====
Diluted, as reported	\$0.81	\$0.59	\$0.41	\$0.36
	=====	=====	=====	=====
Diluted, pro forma	\$0.79	\$0.58	\$0.40	\$0.35
	=====	=====	=====	=====

In December 2004, the FASB issued SFAS No. 123(R), "Share-Based Payment", which is a revision to SFAS No. 123, "Accounting for Stock Based Compensation". SFAS 123(R) requires all share-based payments to employees, including stock options, to be expensed based on their fair values over the required award service period. Although it is difficult to predict the exact impact the adoption of SFAS 123(R) will have on the Company's consolidated earnings due to the number of variables involved, we believe the above pro forma disclosures provide an appropriate indicator of the level of expense that may be recognized upon adoption of the statement. The SEC has amended the compliance dates of SFAS 123(R) requiring adoption in the first fiscal year beginning after June 15, 2005. The Company intends to adopt SFAS 123(R) on June 1, 2006.

Edgar Filing: BIOMET INC - Form 10-Q

NOTE 2: COMPREHENSIVE INCOME.

Other comprehensive income includes foreign currency translation adjustments and unrealized appreciation of available-for-sale securities, net of taxes. Other comprehensive income for the three months ended November 30, 2005 and 2004 was \$(3,620,000) and \$17,069,000, respectively. Other comprehensive income for the six months ended November 30, 2005 and 2004 was \$(28,924,000 and \$18,531,000, respectively. Total comprehensive income combines reported net income and other comprehensive income. Total comprehensive income for the three months ended November 30, 2005 and 2004 was \$97,658,000 and \$108,268,000, respectively. Total comprehensive income for the six months ended November 30, 2005 and 2004 was \$172,653,000 and \$170,163,000, respectively.

NOTE 3: INVENTORIES.

Inventories at November 30, 2005 and May 31, 2005 are as follows:

	November 30, 2005	May 31, 2005
	-----	-----
	(in thousands)	
Raw materials	\$ 56,005	\$ 50,676
Work-in-process	57,411	56,610
Finished goods	216,708	200,041
Consigned distributor	165,500	162,464
	-----	-----
	\$495,624	\$469,791
	=====	=====

NOTE 4: COMMON SHARES.

During the six months ended November 30, 2005, the Company issued 421,441 Common Shares upon the exercise of outstanding stock options for proceeds aggregating \$7,718,000. Purchases of Common Shares pursuant to the Common Share Repurchase Programs aggregated 2,774,600 shares for \$97,929,000 during the six months ended November 30, 2005.

NOTE 5: EARNINGS PER SHARE.

Earnings per common share amounts ("basic EPS") are computed by dividing net income by the weighted average number of common shares outstanding and excludes any potential dilution. Earnings per common share amounts assuming dilution ("diluted EPS") are computed by reflecting potential dilution from the exercise of stock options.

NOTE 6: INCOME TAXES.

The difference between the reported provision for income taxes and a provision computed by applying the federal statutory rate to pre-tax accounting income is primarily attributable to state income taxes, tax benefits relating to operations in Puerto Rico, tax-exempt income, tax credits and the write-off of in-process research and development which is not tax affected.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FINANCIAL CONDITION AS OF November 30, 2005

The Company's cash and investments decreased \$9,547,000 to \$167,527,000 at

Edgar Filing: BIOMET INC - Form 10-Q

November 30, 2005. This decrease resulted from the \$62,473,000 dividend payment made during the first quarter and the \$97,929,000 used to purchase shares during the first six months pursuant to the Company's share repurchase programs, offset by positive cash flow from operations. On December 21, 2005, the Company announced an expansion to its discretionary share repurchase program to add an additional \$100 million.

Cash flows provided by operating activities were \$178,902,000 for the first six months of fiscal 2006 compared to \$179,183,000 in 2005. The primary sources of fiscal year 2006 cash flows from operating activities were net income and depreciation. The primary uses were increase in accounts receivable and inventory. The Company's major cash collection day is Monday, and as the Company's quarter end moves further away from a Monday, accounts receivable ending balances increase. Inventories increased from new product introductions, specifically new knee systems introduced in the US and Europe. In addition, the Company is building inventory for the launch of its new bone cements, while maintaining adequate supplies of its previous products. Accounts and notes receivable and inventory balances were decreased during the six month period by \$13.7 million and \$15.8 million, respectively, due to currency exchange rates.

Cash flows used in investing activities were \$46,755,000 for the first six months of fiscal 2006 compared to \$310,463,000 in 2005. The primary use of cash flows from investing activities in fiscal 2006 has been for capital expenditures. The Company continues to upgrade its instruments used in various international markets and to support the new implant systems being launched. In addition, 3i is currently expanding its manufacturing facilities in Florida.

Cash flows used in financing activities were \$141,566,000 for the first six months of fiscal 2006 compared to a source of \$67,289,000 in 2005. The primary uses of cash flows in financing activities were the cash dividend paid and the share repurchase programs. In July 2005, the Company's Board of Directors declared a cash dividend of twenty five cents (\$0.25) per share payable to shareholders of record at the close of business on July 16, 2005. Over the last twelve quarters, the Company has used \$939,500,000 to purchase its common stock.

Currently available funds, together with anticipated cash flows generated from future operations are believed to be adequate to cover the Company's anticipated cash requirements, including capital expenditures, research and development costs and share repurchases.

RESULTS OF OPERATIONS FOR THE SIX MONTHS ENDED NOVEMBER 30, 2005 AS COMPARED TO THE SIX MONTHS ENDED NOVEMBER 30, 2004

Net sales increased 9% to \$979,593,000 for the six months ended November 30, 2005, from \$894,834,000 for the same period last year. This sales growth includes a minimal impact from foreign currency. The Company's sales were impacted by the hurricane activity in the gulf coast and Florida, resulting in an estimated revenue loss of approximately \$4.5 million. The Company's U.S.-based revenue increased 6% to \$642,927,000 during the first six months of fiscal 2006, while foreign sales increased 16% (15% currency adjusted) to \$336,666,000. The Company's worldwide sales of reconstructive products during the first six months of fiscal 2006 were \$660,154,000, representing a 13% increase compared to the first six months of last year. Sales of fixation products were \$124,854,000 for the first six months of fiscal 2006, representing a 1% increase as compared to the same period in 2005. Sales of spinal products were \$110,353,000 for the first six months of fiscal 2006, representing a 4% increase as compared to the same period in 2005. Fixation and spinal product sales have been negatively impacted by the combination of the Interpore and EBI sales forces, and at the same time the integration of Biomet's internal fixation sales force into EBI's fixation sales force. During the fourth quarter of last year and the first quarter of this year,

Edgar Filing: BIOMET INC - Form 10-Q

EBI has introduced several new products in both the internal fixation and spinal implant markets that we believe will have a positive impact on sales in the future. In addition, during the first quarter, the Company announced the appointment of Bart Doedens, M.D., as the new president of EBI's operations following the resignation of James R. Pastena. EBI's fixation, spinal stimulation and softgoods and bracing products have continued to underperform management's expectations and it is hoped that Dr. Doedens will provide the leadership necessary to improve EBI's performance in these markets. The Company's sales of other products totaled \$84,232,000, representing a 3% increase over the first six months of fiscal year 2005.

Cost of sales decreased as a percentage of net sales to 28.0% for the first six months of fiscal 2006 from 28.7% for the same period last year. The components of this change are a decrease of 1.6% relating to the impact of inventory step-up from acquisitions on last year's cost of goods sold, offset by an increase of 0.5% due to an unanticipated, retroactive price increase from the supplier of Biomet's antibiotic delivery system in Europe and 0.4% from higher growth rates in foreign sales, where gross margins are lower, versus domestic sales. Selling, general and administrative expenses, as a percentage of net sales, increased to 36.7% compared to 36.5% for the first six months last year. This increase is mainly attributable to the national branding campaign commenced during the first quarter. Research and development expenditures increased 10.6% during the first six months to \$42,119,000 reflecting the Company's continued emphasis on new product introductions. In-process research and development expense relates to the acquired in-process research and development related to the Interpore acquisition completed last year, which was written off at the acquisition date. Operating income increased 23% from \$246,880,000 for the first six months of fiscal 2005, to \$303,733,000 for the first six months of fiscal 2006. After adjusting operating income for acquisition related expenses in fiscal 2005, operating income increased 6%. Other income increased from \$(484,000) last year to \$313,000 this year. Other income has been positively impacted by higher daily balances of investments during the first quarter and an increase in interest rates. The effective income tax rate decreased to 33.7% for the first six months of fiscal year 2006 from 38.5% last year primarily as a result of the write-off of in-process research and development last year not being tax affected.

These factors resulted in a 33% increase in net income from \$151,632,000 to \$201,577,000, a 35% increase in basic earnings per share from \$0.60 to \$0.81 and a 37% increase in diluted earnings per share from \$0.59 to \$0.81 for the periods presented. Before acquisition related expenses last year, net income increased by 8%, basic earnings per share increased 9% and diluted earnings per share increased 11% for the periods presented.

RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED NOVEMBER 30, 2005 AS COMPARED TO THE THREE MONTHS ENDED NOVEMBER 30, 2004

Net sales increased 8% to \$494,690,000 for the second quarter ended November 30, 2005, from \$456,674,000 for the same period last year. This sales growth includes a minimal impact from foreign currency. The Company's sales were impacted by the hurricane activity in the gulf coast and Florida, resulting in an estimated revenue loss of approximately \$4.5 million. The Company's U.S.-based revenue increased 5% to \$325,602,000 during the second quarter of fiscal 2006, while foreign sales increased 15% to \$169,088,000. Excluding the positive foreign exchange adjustment, foreign revenue increased 14%. The Company's worldwide sales of reconstructive products during the second quarter of fiscal 2006 were \$336,339,000, representing a 12% increase compared to the second quarter of last year. Sales of fixation products were \$60,675,000 for the second quarter fiscal 2006, representing a slight increase as compared to the same period in 2005. Sales of spinal products were \$55,027,000 for the

Edgar Filing: BIOMET INC - Form 10-Q

second quarter of fiscal 2006, representing a 3% increase as compared to the same period in 2005. Fixation and spinal product sales have been negatively impacted by the combination of the Interpore and EBI sales forces, and at the same time the integration of Biomet's internal fixation sales force into EBI's fixation sales force. The Company expects this negative impact to continue during the next quarter. The Company's sales of other products totaled \$42,649,000, representing a 2% increase over the second quarter of fiscal year 2005.

Cost of sales decreased as a percentage of net sales to 28.2% for the second quarter of fiscal 2006 from 28.7% for the same period last year. The components of this change are a decrease of 1.7% relating to the impact of inventory step-up from acquisitions on last year's cost of goods sold, offset by an increase of 0.6% due to an unanticipated, retroactive price increase from the supplier of Biomet's antibiotic delivery system in Europe and 0.6% from higher growth rates in foreign sales, where gross margins are lower, versus domestic sales. Selling, general and administrative expenses, as a percentage of net sales, increased to 36.7% compared to 36.4% for the second quarter last year. This increase is mainly attributable to the national branding campaign commenced during the first quarter. Research and development expenditures increased 9% during the second quarter to \$21,303,000 reflecting the Company's continued emphasis on new product introductions. Operating income increased 9% from \$139,648,000 for the second quarter of fiscal 2005, to \$152,323,000 for the second quarter of fiscal 2006. After adjusting operating income for acquisition related expenses in fiscal 2005, operating income increased 4%. Other income decreased from \$244,000 last year to \$(245,000) this year. Other income has been negatively impacted by a reduction in cash available for investments due to the large amount of shares repurchased during the second quarter. The effective income tax rate decreased to 33.4% for the quarter from 34.8% last year.

These factors resulted in a 11% increase in net income to \$101,278,000 for the second quarter of fiscal 2006 as compared to \$91,199,000 for the same period in fiscal 2005, while basic and diluted earnings per share increased 14%, from \$0.36 to \$0.41 for the periods presented. Before acquisition related expenses last year, net income increased by 5%, while basic and diluted earnings per share increased 8% for the periods presented.

Item 3. Quantitative and Qualitative Disclosures about Market Risks.

There have been no material changes from the information provided in the Company's Annual Report on Form 10-K for the year ended May 31, 2005.

Item 4. Controls and Procedures.

(a) Evaluation of Disclosure Controls and Procedures. As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of its management, including the Company's Chief Executive Officer and Chief Financial Officer, of the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934). Based on this evaluation, the Company's Chief Executive Officer and Chief Financial Officer have concluded that the Company's disclosure controls and procedures are effective in timely notification to them of information the Company is required to disclose in its periodic SEC filings and in ensuring that this information is recorded, processed summarized and reported within the time periods specified in the SEC's rules and regulations.

(b) Changes in Internal Control. During the second quarter of fiscal 2006 covered by this report, there have been no changes in internal control over

Edgar Filing: BIOMET INC - Form 10-Q

financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

(c) Stock Repurchases

As of November 30, 2005, the Company had two publicly-announced share repurchase programs outstanding. The first, announced March 22, 2005, approved the purchase of shares up to \$100 million in open market or privately negotiated transactions expiring March 21, 2006. The second, announced June 30, 2005, approved the purchase of 2,500,000 shares to be automatically purchased in equal installments over a twelve-month period expiring June 29, 2006. Information on shares repurchased in the most recently completed quarter is as follows:

Period	Total Number of shares Purchased	Average Price Paid Per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans	Maximum Number of Shares (or Approximate Dollar Value) that May Yet be Purchased Under the Plans
September 1-30	210,000	\$36.57	210,000	1,870,000 shares and \$58,049,629
October 1-31	1,397,200	33.76	1,397,200	1,660,000 shares and \$18,017,406
November 1-30	210,000	36.33	210,000	1,450,000 shares and \$18,017,406
Total	1,817,200	34.38	1,817,200	1,450,000 shares and \$18,017,406

Item 6. Exhibits and Reports on Form 8-K

(a) Exhibits. See Index to Exhibits.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIOMET, INC.

DATE: 1/09/2006

BY: /s/ Gregory D. Hartman

Gregory D. Hartman
Senior Vice President - Finance
(Principal Financial Officer)

(Signing on behalf of the registrant
and as principal financial officer)

BIOMET, INC.

FORM 10-Q

Edgar Filing: BIOMET INC - Form 10-Q

INDEX TO EXHIBITS

Exhibits.	Descriptions.
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Written Statement of Chief Executive Officer and Chief Financial Officer Pursuant to Sections 906 of the Sarbanes-Oxley Act of 2002.